IRIS
LAZZARIN, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.184
EU - Europa 5.028
AS - Asia 4.935
SA - Sud America 1.096
Continente sconosciuto - Info sul continente non disponibili 279
AF - Africa 87
OC - Oceania 5
Totale 16.614
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.964
RU - Federazione Russa 2.803
CN - Cina 1.725
SG - Singapore 1.650
BR - Brasile 900
SE - Svezia 731
HK - Hong Kong 588
VN - Vietnam 449
IT - Italia 367
RO - Romania 269
FR - Francia 241
DE - Germania 205
BD - Bangladesh 119
GB - Regno Unito 114
CA - Canada 101
IN - India 98
AR - Argentina 76
FI - Finlandia 74
MX - Messico 53
ID - Indonesia 45
TR - Turchia 41
ZA - Sudafrica 39
PL - Polonia 38
NL - Olanda 35
EC - Ecuador 34
IQ - Iraq 34
CO - Colombia 32
AT - Austria 30
ES - Italia 30
JP - Giappone 26
IE - Irlanda 21
PK - Pakistan 21
UA - Ucraina 17
VE - Venezuela 16
AE - Emirati Arabi Uniti 15
LT - Lituania 15
MY - Malesia 15
PH - Filippine 15
UZ - Uzbekistan 15
MA - Marocco 13
SA - Arabia Saudita 13
CL - Cile 12
JM - Giamaica 11
TN - Tunisia 11
NP - Nepal 10
GT - Guatemala 8
HN - Honduras 8
NI - Nicaragua 8
PY - Paraguay 8
BO - Bolivia 7
CR - Costa Rica 7
DZ - Algeria 7
LU - Lussemburgo 7
MD - Moldavia 7
CZ - Repubblica Ceca 6
TH - Thailandia 6
BE - Belgio 5
EG - Egitto 5
EU - Europa 5
IL - Israele 5
IR - Iran 5
KW - Kuwait 5
OM - Oman 5
PA - Panama 5
PE - Perù 5
UY - Uruguay 5
AU - Australia 4
KE - Kenya 4
AZ - Azerbaigian 3
BB - Barbados 3
BS - Bahamas 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
JO - Giordania 3
KG - Kirghizistan 3
KR - Corea 3
KZ - Kazakistan 3
PR - Porto Rico 3
QA - Qatar 3
TT - Trinidad e Tobago 3
AL - Albania 2
BG - Bulgaria 2
GE - Georgia 2
LB - Libano 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BF - Burkina Faso 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GF - Guiana Francese 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
Totale 16.330
Salva come PNG Salva come JPEG
Città #
Dallas 1.433
Singapore 685
Moscow 643
San Jose 596
Hong Kong 578
Ashburn 503
Shanghai 283
Council Bluffs 257
Hefei 232
Lawrence 220
Princeton 219
Beijing 202
Lauterbourg 201
New York 177
Ho Chi Minh City 162
Milan 122
Hanoi 97
São Paulo 97
Los Angeles 96
Santa Clara 81
Nuremberg 57
Helsinki 53
Boardman 44
Phoenix 42
Munich 41
Orem 40
Warsaw 35
Guangzhou 34
Rome 34
Montreal 32
Chennai 29
Denver 29
Atlanta 28
Seattle 26
Washington 26
Mexico City 25
Tokyo 25
Chicago 24
Pune 24
Johannesburg 23
Brooklyn 22
Curitiba 21
Frankfurt am Main 21
Manchester 21
Da Nang 20
Houston 19
Rio de Janeiro 19
London 18
Belo Horizonte 17
Philadelphia 17
Poplar 17
Ankara 16
Buffalo 16
Dublin 16
Haiphong 16
Miami 16
Shenzhen 16
Toronto 16
Boston 15
Stockholm 15
Tashkent 15
Turku 15
Amsterdam 14
Vienna 14
Brasília 13
Campinas 13
Hangzhou 13
Hải Dương 12
The Dalles 12
Baghdad 11
Goiânia 11
Guayaquil 11
Porto Alegre 11
Quito 11
Tianjin 11
Charlotte 10
Las Vegas 10
Reston 10
Columbus 9
Kingston 9
Kuala Lumpur 9
Querétaro 9
San Francisco 9
Barnet 8
Bogotá 8
Buenos Aires 8
Cesano Boscone 8
Istanbul 8
New Delhi 8
Salvador 8
Betim 7
Detroit 7
Dhaka 7
Ha Long 7
Kassel 7
Managua 7
Mumbai 7
Quanzhou 7
Sorocaba 7
São José do Rio Preto 7
Totale 8.297
Salva come PNG Salva come JPEG
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 1.368
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 213
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 185
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 156
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 155
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 154
Biobanking for COVID-19 research 149
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 132
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 123
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 119
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 119
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 118
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 117
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 115
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 114
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 113
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 112
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 107
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 106
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients with Advanced Liver Disease during Anti-HCV Treatment with Direct-Acting Antiviral Regimens Including Ribavirin 104
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 103
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 103
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 102
Bictegravir 102
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 102
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 102
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 101
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 99
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 96
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 96
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 96
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 95
ABC of AIDS: Treatment of infections and antiviral agents 94
Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study 92
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 92
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 89
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 88
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 88
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 88
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 86
Experiences with immunomodulant agents in HIV infections 86
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 85
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial 85
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 85
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 85
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 84
Hepatitis delta infection among persons living with HIV in Europe 84
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan 83
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 81
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 80
Analysis of impediments to the maintenance in care of people with HIV in Italy 79
Immunological status in heroin addicts: effects of methadone maintenance treatment 78
Darunavir for the treatment of HIV infection 78
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population 78
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 77
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe 77
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 76
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 75
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 75
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 75
Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV 74
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 74
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 74
Early diagnosis of HIV infection in infants 73
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 72
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 72
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 72
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 71
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman 71
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 71
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 71
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 71
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 71
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 70
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 70
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 70
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 69
Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study 69
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 69
Impact of HAART on liver histology of HIV/HCV coinfected patients 68
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 68
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 68
No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study 67
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 67
T-lymphocyte subsets and delayed type hypersensitivity as classification parameters for HIV infection among drug-addicts 66
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 66
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy 66
Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women 65
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 65
Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: An Italian pilot study in a dental clinic 65
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 65
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients 64
Polymorphonuclear leucocytes functions from premature infants after prevention of respiratory distress syndrome with betamethasone and ambroxol 63
Immune recovery and T cell subset analysis during effective treatment with maraviroc 63
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients 63
Risk behaviour and HTLV-1 seropositivity in injecting drug users 63
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 63
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort 62
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) 62
Milan as possible starting point of LAV/HTLV III epidemic among Italian drug addicts 62
Totale 10.114
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.248
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.248
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024605 7 29 81 49 45 137 13 68 0 15 80 81
2024/20253.101 375 58 37 81 83 256 711 232 487 360 162 259
2025/202610.349 718 880 1.425 1.260 633 308 927 646 2.491 559 245 257
2026/2027916 238 532 146 0 0 0 0 0 0 0 0 0
Totale 16.614